Peregrine Pharmaceuticals reported $145.94M in Current Assets for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Current Assets Change
Agenus AGEN:US USD 251.43M 37.5M
Amgen AMGN:US USD 22.19B 1.88B
AstraZeneca AZN:LN USD 20.22B 693M
Celldex Therapeutics CLDX:US USD 334.6M 33.38M
GlaxoSmithKline GSK:LN GBP 20.77B 520M
Immunogen IMGN:US USD 330.42M 63.51M
Intrexon XON:US USD 162.81M 1.81M
Karyopharm Therapeutics KPTI:US USD 222.68M 19.77M
Macrogenics MGNX:US USD 147.81M 19.82M
Mannkind MNKD:US USD 218.38M 24.9M
Minerva Neurosciences NERV:US USD 44.84M 5.2M
Newlink Genetics NLNK:US USD 78.83M 6.16M
Novartis NOVN:VX USD 36.91B 44M
Novavax NVAX:US USD 1.76B 376.04M
Peregrine Pharmaceuticals PPHM:US USD 145.94M 34.69M
Repligen RGEN:US USD 953.23M 22.76M
Roche Holding ROG:VX 30.32B 5.31B
Xencor XNCR:US USD 668M 82.06M